Added to YB: 2026-09-18
Pitch date: 2026-09-16
TARA [neutral]
Protara Therapeutics, Inc.
Author Info
No bio for this author
Company Info
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
Market Cap
$221.6M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.83
P/E
-2.77
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Week 2 Day 2 part 2 - Protara Therapeutics, Inc.
TARA (update): Protara has several potential routes to value, including TARA-002 in bladder cancer and pediatric lymphatic malformations, but still needs more mature efficacy, durability and regulatory evidence. Management reported 55% 12-month complete response in BCG-naïve NMIBC and 100% clinical success among lymphatic-malformation treatment completers; small interim cohorts, an unfinalized ADVANCED-3 redesign and unproven IV choline pathways remain key risks.
Read full article (2 min)